The second generation ALKi brigatinib and alectinib have demonstrated efficacy in second line treatment in crizotinib-refractory ALK+ NSCLC patients, and in the first-line setting in ALEX (alectinib) and ALTA-1L (brigatinib) clinical trials. This evidence concerns the gene ALK and non-small cell lung carcinoma.